BioWorld

Aug. 23, 2006

View Archived Issues

Shell Firm Acquiring Protalix, Phase III Gaucher's Therapy

Public shell company Orthodontix Inc. is gaining a Phase III-ready drug for Gaucher's disease along with a plant-cell bioreactor for making proteins in its merger with Israeli firm Protalix Ltd. (BioWorld Today) Read More

Belgian Firm Peakadilly Gets €14.5M In Series A

No Abstract Read More

Anthracycline Prodrug Added To Innovive's Cancer Pipeline

Read More

Thiakis Series A Brings In £10M For Obesity Program

Read More

Appointments And Advancements

Read More

Clinic Roundup

Read More

Other News To Note

Read More